Your browser doesn't support javascript.
loading
Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study
Zheng, J; Xiao, T; Ye, P; Miao, D; Wu, H.
Afiliação
  • Zheng, J; Chinese People's Liberation Army General Hospital. Department of Geriatric Cardiology. Beijing. CN
  • Xiao, T; Chinese People's Liberation Army General Hospital. Department of Geriatric Cardiology. Beijing. CN
  • Ye, P; Chinese People's Liberation Army General Hospital. Department of Geriatric Cardiology. Beijing. CN
  • Miao, D; Chinese People's Liberation Army General Hospital. Department of Geriatric Cardiology. Beijing. CN
  • Wu, H; Chinese People's Liberation Army General Hospital. Department of Geriatric Cardiology. Beijing. CN
Braz. j. med. biol. res ; 50(10): e6363, 2017. tab
Artigo em Inglês | LILACS | ID: biblio-888933
Biblioteca responsável: BR1.1
ABSTRACT
This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharmaceutical excipients). Physical examination outcomes, lipid profile, high sensitivity C-reactive protein (hs-CRP) levels, matrix metalloproteinases-9 (MMP-9) levels, and arterial outcomes, including stiffness parameter (β), pressure-strain elasticity modulus (Ep), arterial compliance (AC), augmentation index (AI), and one-point pulse wave velocity (PWVβ) were obtained at baseline and after 6 months of the intervention. Xuezhikang significantly reduced β (8.4±3.1 vs 6.8±2.1, P=0.007), Ep (122.8±43.9 vs 100.7±33.2, P=0.009), PWVβ (6.7±1.2 vs 6.1±1.0, P=0.013), low-density lipoprotein cholesterol (3.4±0.6 vs 2.9±0.5, P=0.001), hs-CRP [2.1 (0.4-10.0) vs 1.4 (0.3-4.1), P=0.020], and MMP-9 (17.2±2.4 vs 12.7±3.8, P <0.001) compared to baseline. The placebo had no effect on these parameters. The changes of PWVβ in the xuezhikang group was significantly associated with the changes of hs-CRP and MMP-9 (r=0.144, P=0.043; r=0.278, P=0.030, respectively) but not with lipid profile changes. Our research showed xuezhikang can improve the parameters of arterial stiffness in hypertensive patients, and its effect was independent of lipid lowering.
Assuntos


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Medicamentos de Ervas Chinesas / Rigidez Vascular / Hipertensão Essencial Tipo de estudo: Ensaio clínico controlado Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Braz. j. med. biol. res Assunto da revista: Biologia / Medicina Ano de publicação: 2017 Tipo de documento: Artigo / Documento de projeto País de afiliação: China Instituição/País de afiliação: Chinese People's Liberation Army General Hospital/CN

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Medicamentos de Ervas Chinesas / Rigidez Vascular / Hipertensão Essencial Tipo de estudo: Ensaio clínico controlado Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Braz. j. med. biol. res Assunto da revista: Biologia / Medicina Ano de publicação: 2017 Tipo de documento: Artigo / Documento de projeto País de afiliação: China Instituição/País de afiliação: Chinese People's Liberation Army General Hospital/CN
...